Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Non-Current Assets: 2009-2025

Historic Non-Current Assets for China Pharma Holdings (CPHI) over the last 17 years, with Sep 2025 value amounting to $13.5 million.

  • China Pharma Holdings' Non-Current Assets rose 38.54% to $13.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.5 million, marking a year-over-year increase of 38.54%. This contributed to the annual value of $11.6 million for FY2024, which is 10.93% up from last year.
  • Latest data reveals that China Pharma Holdings reported Non-Current Assets of $13.5 million as of Q3 2025, which was up 21.78% from $11.1 million recorded in Q2 2025.
  • Over the past 5 years, China Pharma Holdings' Non-Current Assets peaked at $15.0 million during Q1 2021, and registered a low of $9.5 million during Q3 2023.
  • Over the past 3 years, China Pharma Holdings' median Non-Current Assets value was $11.1 million (recorded in 2025), while the average stood at $10.9 million.
  • As far as peak fluctuations go, China Pharma Holdings' Non-Current Assets fell by 24.53% in 2022, and later spiked by 38.54% in 2025.
  • Quarterly analysis of 5 years shows China Pharma Holdings' Non-Current Assets stood at $13.6 million in 2021, then fell by 12.81% to $11.8 million in 2022, then fell by 11.40% to $10.5 million in 2023, then increased by 10.93% to $11.6 million in 2024, then surged by 38.54% to $13.5 million in 2025.
  • Its last three reported values are $13.5 million in Q3 2025, $11.1 million for Q2 2025, and $11.4 million during Q1 2025.